skip to Main Content
  • This page as PDF
April 28, 2021 12:00 - 1:00 PM ET

Navigating Drug Pricing Proposals and the Role of Value


Join Avalere’s panel of data analytics, market access, and policy experts for a discussion on the potential for federal drug pricing reform in Congress or via administrative action.

With Congress poised to consider a second reconciliation package, drug pricing reforms are likely to be on the agenda as a means to pay for permanent coverage expansion and other top priorities. In addition to the expected legislative landscape and as the Biden Administration takes shape, the debate over drug pricing reforms, especially “government negotiation,” is likely to reignite through CMMI and other regulatory vehicles.

Key Topics

  • Part D redesign
  • Government negotiation
  • International reference pricing
  • Linking payment to evidence and value
  • Part B drug reimbursement changes
  • Inflation rebates


Matt Kazan , Principal, Policy

Matt Kazan provides strategic advice to health plan and life sciences clients navigating the complex legislative and regulatory policy environment, with a particular expertise in Medicare Part D and Medicare Advantage.

Lance Grady , Practice Director, Commercialization & Regulatory Strategy

As the leader of the Market Access Practice, Lance Grady devises commercialization strategies focused on value, access, and reimbursement.

Brian Leinwand , Associate Principal, Health Economics & Advanced Analytics

Brian Leinwand provides strategic health economics support throughout a product’s life-cycle and helps clients build evidence packages that demonstrate and support the value of their products.

Milena Sullivan , Principal, Policy

Milena Sullivan advises life sciences clients on the impact of the evolving healthcare policy landscape on their commercial, access, and advocacy priorities.

From beginning to end, our team synergy
produces measurable results. Let's work together.
Back To Top